Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUMMIT phase II trial of sorafenib versus placebo in advanced medullary thyroid carcinoma
2011-006250-90Phase 2Active
- Sponsor
- EANM Research
- Start
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Medullary Thyroid Cancer (MTC) comparing Sorafenib with Placebo (2 arms). Primary endpoint: Progression-free survival. Started Mar 2012; status: active.
02
Drugs
sorafenib
03
Conditions
Medullary Thyroid Cancer (MTC)
Beyond the preview
Go deeper on 2011-006250-90.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-006250-90.